KMT2D and hepatocellular carcinoma: Moreover, patients with high expression of TET2 and KMT2D present a better prognostic outcome in contrast to patients with low expression of the counterparts (Fig. 6D), implying that combination analysis of TET2 and KMT2D harbors clinical potential for patients with HCC.